Core Viewpoint - The announcement indicates that the company, 石药集团 (Shijiazhuang Pharmaceutical Group), will purchase a total of 6 million shares of its own stock by October 14, 2025, for the benefit of selected participants through a trust arrangement [1] Group 1 - The company has appointed a trustee to execute the share purchase plan [1] - The shares will be held in trust for the benefit of selected participants [1] - The total number of shares to be purchased is 6 million [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 根據本公司股份獎勵計劃 在市場上購買股份 謹此 提述 石藥 集團 有限 公司（「本 公司」）於 2018 年8 月 20 日 有關 刊發 採納 本公 司限 制性 股份 獎勵計劃（「該計劃」）之公告（「該公告」）。誠如本公司日期為2024年5月21日之自願公告所披 露，該計劃之條款其後已作出修訂。除本公告另有界定外，本公告所用詞彙與該公告所界 定者具有相同涵義。 於2025年10月14日，受託人根據該計劃之條款及條件在市場上購買合共6,000,000股本公司 股份，並為獲選參與者之利益以信託方式持有該等股份。受託人於2025年10月14日所購買 及以信託方式持有之股份詳情如下： | 所購買股份總數： | 6,000,000股股份 | | --- | --- | | 所購買股份佔目前已發行股份總數百分比： | 約0.052 % | | 每股平均價格： | 約8.8436港元 | | 所購買股份之總代價： | ...

Core Viewpoint - The article discusses the recent market fluctuations in Hong Kong, highlighting the significant drop in major indices and the performance of specific stocks, while also noting the potential investment opportunities arising from these short-term market movements [2][12]. Market Performance - On October 14, Hong Kong's major stock indices experienced declines, with the Hang Seng Index falling by 1.73% to 25,441.35 points, the Hang Seng Tech Index dropping by 3.62% to 5,923.26 points, and the Hang Seng China Enterprises Index decreasing by 1.55% to 9,079.16 points [2]. - The trading volume for the day was 398.91 billion HKD, with net inflows from southbound funds amounting to 8.603 billion HKD [2]. Stock Movements - Among the constituents of the Hang Seng Index, 19 stocks rose while 68 fell. Notable declines included SMIC down 8.48%, CSPC Pharmaceutical down 7.08%, and Kuaishou down 6.77% [4][5]. - The semiconductor sector saw a significant downturn, with the Wind Hong Kong Semiconductor Index dropping by 9.20% at one point, closing down 8.05% [15]. HMVOD Video Developments - HMVOD Video experienced a dramatic increase in stock price, peaking at a 210.22% rise before closing with a 74.45% gain, following the announcement of a partnership with Mango Super Media's subsidiary for a new program [22][26]. - The partnership involves the licensing of a program titled "Amazing Boy," with an authorization fee of 2 million RMB, pending further negotiations [22][26]. Investment Insights - Invesco's Chief Investment Officer, Ma Lei, indicated that current market volatility may present a buying opportunity for long-term investors, particularly in companies with strong fundamentals and pricing power [12][13]. - The article emphasizes the importance of bottom-up stock selection in navigating the current market environment, suggesting a focus on resilient companies amid trade uncertainties [13].

Core Viewpoint - Hong Kong Exchanges and Clearing Limited (HKEX) plans to launch the Hang Seng Biotechnology Index Futures on November 28, 2025, providing effective risk management tools for the rapidly growing biotechnology sector [2][3][4]. Group 1: Product Details - The new futures contract will have the code HBI, with a contract multiplier of HKD 50 per index point, and will be available for trading in the current month, the next three months, and the following three quarterly months [3]. - The first six months of trading will be exempt from the Securities and Futures Commission transaction fees, with the margin rate to be announced later [3][4]. Group 2: Market Context - The biotechnology sector is currently one of the hottest and fastest-growing industries in the Hong Kong capital market, driven by technological innovation and global healthcare demand [4]. - The Hang Seng Biotechnology Index has recorded a 63.61% increase over the past year, significantly outperforming the Hang Seng Index, which rose by 20.62% [4]. - Year-to-date, the Hang Seng Biotechnology Index has surged by 90.33%, surpassing the Hang Seng Technology Index's increase of 37.54% [4]. Group 3: Major Constituents - The index tracks the 30 largest biotechnology, pharmaceutical, and medical device companies listed on the Hong Kong Stock Exchange, with major constituents including WuXi Biologics, BeiGene, and Innovent Biologics [4][5]. - The top ten weighted stocks in the index include: - WuXi Biologics (10.83% weight, market cap HKD 120.825 billion) - BeiGene (10.21% weight) - Innovent Biologics (9.18% weight, market cap HKD 139.0 billion) - And others, contributing to a diverse representation of the sector [5]. Group 4: Industry Growth - Since the listing reforms in 2018, the biotechnology and healthcare sectors have become the fastest-growing industries in Hong Kong, with over 260 companies listed and a total market capitalization exceeding HKD 4.8 trillion, quadrupling from approximately HKD 1.2 trillion at the end of 2018 [6].

Core Viewpoint - The pharmaceutical sector, particularly innovative drugs, is experiencing significant volatility, with both A-shares and Hong Kong stocks showing sharp declines in recent trading sessions, indicating potential investment opportunities amidst market fluctuations [1][3][5]. Group 1: A-Share Market Performance - A-share market saw major declines in innovative drug stocks, with Beida Pharmaceutical dropping by 10.63%, Hengrui Medicine down 4.05%, and Baili Tianheng falling 6.18%, leading to a 2.21% drop in the only drug ETF (562050) [1]. - The CXO sector also faced declines, with WuXi AppTec falling 3.82%, while the largest medical ETF (512170) only decreased by 1.32%, indicating some resilience in the market [1]. Group 2: Hong Kong Market Performance - The Hong Kong pharmaceutical market experienced even more volatility, with innovative drug stocks like Kelun-Bio dropping 9.82% and major players like CSPC Pharmaceutical and Innovent Biologics falling over 6% [3]. - The Hong Kong Stock Connect innovative drug ETF (520880) opened up 1.86% but ended the day down 4.22%, marking its largest single-day drop since inception, with a trading volume of 4.1 billion [3]. Group 3: Investment Sentiment and Opportunities - Despite the ongoing market downturn, there is a noticeable increase in buying interest, as evidenced by a significant inflow of capital into the medical ETFs, suggesting that investors may be looking for "golden pit" opportunities in the pharmaceutical sector [5][6]. - Analysts suggest that the recent declines may be a release of short-term risks and emotional volatility, with potential for greater opportunities than risks if the market undergoes significant adjustments [5]. Group 4: Market Dynamics and Future Outlook - The fund manager of the Hong Kong Stock Connect innovative drug ETF highlighted the interconnectedness of the US and Chinese biopharmaceutical industries, suggesting that recent tariff tensions may lead to a "TACO trade" strategy, where investors anticipate a reversal of aggressive policies [6]. - The innovative drug sector is supported by strong fundamentals, including innovation capabilities and global competitiveness, which remain unchanged despite market fluctuations [6]. - With the global liquidity easing cycle initiated by the Federal Reserve, many institutions view Hong Kong stocks as undervalued and a favorable investment opportunity [7].

Core Viewpoint - Domestic pharmaceutical companies are intensifying competition in the GLP-1 market, particularly focusing on weight loss drugs, with Shijiazhuang Pharmaceutical Group making significant advancements in this area [1][2]. Group 1: Product Development and Clinical Trials - Shijiazhuang Pharmaceutical Group's subsidiary, Shijiazhuang Pharmaceutical Baike, has received regulatory acceptance for the new drug application of its innovative GLP-1 drug, Idaglutide α injection, aimed at long-term weight management in overweight or obese adults [1][2]. - The drug is based on a pivotal Phase III clinical trial involving overweight adults with at least one weight-related comorbidity, showing significant reductions in weight, waist circumference, blood sugar, blood pressure, and blood lipids compared to placebo [2][4]. - Idaglutide α injection is a recombinant human glucagon-like peptide-1 (hGLP-1) Fc fusion protein administered weekly, combining weight loss and blood sugar-lowering effects [1][2]. Group 2: Competitive Landscape - Idaglutide α injection is an innovative drug developed by Shijiazhuang Pharmaceutical Group, contrasting with the recently submitted application for the generic drug Semaglutide, highlighting the company's focus on original research [3][4]. - The competitive landscape includes multinational companies like Eli Lilly and Novo Nordisk, which are advancing next-generation weight loss therapies, shifting from single-target to multi-target approaches to enhance drug efficacy and safety [4][7]. - The global market for GLP-1 receptor agonists (GLP-1RA) is projected to reach $51.8 billion in 2024, with a 40% year-on-year growth, driven by significant demand in the weight loss segment [7]. Group 3: Future Prospects and Strategic Positioning - Shijiazhuang Pharmaceutical Group is also developing a long-acting GLP-1 drug, Semaglutide long-acting injection (SYH9017), which is expected to receive clinical approval for weight loss indications in December 2024 [5]. - The domestic weight loss drug market is becoming increasingly crowded, with multiple companies, including Shijiazhuang Pharmaceutical Group, submitting applications for Semaglutide, as the core patent for Novo Nordisk's Semaglutide is set to expire in 2026 [8].

Market Overview - The Hong Kong stock market experienced a decline, with the Hang Seng Index dropping 1.73% to close at 25,441.35 points, and a total trading volume of 398.91 billion HKD [1] - The recent escalation in US-China trade tensions has increased market uncertainty, leading to heightened volatility [1] Blue Chip Performance - China Merchants Bank (03968) led blue-chip gains, rising 4.7% to 48.16 HKD, contributing 13.25 points to the Hang Seng Index [2] - Other notable blue-chip movements included New Energy (02688) up 3.19%, and Construction Bank (00939) up 2.32%, while Semiconductor Manufacturing International Corporation (00981) fell 8.48% [2] Sector Performance Banking Sector - The banking sector is attracting defensive capital due to increased tariff uncertainties, with stable dividends and improved yield attractiveness post-correction [3] - The profit growth for listed banks in the first half of 2025 is projected at 0.8%, indicating a stable outlook [3] Shipping Sector - Shipping stocks showed strong performance, with China COSCO Shipping (01919) up 4.08% as the US port fee measures are set to take effect [4] - Analysts suggest that Chinese shipping companies may benefit more from the current trade dynamics compared to their US counterparts [4] Semiconductor Sector - Semiconductor stocks faced significant declines, with Hua Hong Semiconductor (01347) down 13.08% and SMIC (00981) down 8.48% [6] - Recent regulatory changes affecting a subsidiary of Wingtech Technology have raised concerns about market sentiment in the semiconductor industry [6] Gold Sector - Gold stocks fell sharply following a significant drop in gold prices, with notable declines in companies like Chifeng Jilong Gold Mining (06693) down 6.8% [5][7] Notable Stock Movements - Zhenjiu Lidu (06979) saw a rise of 5.42% following a leadership change, with the new CEO expected to enhance brand operations [8] - InnoCare Pharma (02577) increased by 4.91% due to advancements in GaN technology in collaboration with NVIDIA [9] - New China Life Insurance (01336) announced a profit increase forecast of 45% to 65% for the first three quarters of 2025, leading to a 3.52% rise in stock price [10]

Market Performance - The Hang Seng Healthcare Index decreased by 2.74% as of October 14, 2025, with mixed performance among constituent stocks [1] - The Hang Seng Healthcare ETF (513060) fell by 1.74%, with a latest price of 0.68 CNY, but has seen an 18.15% increase over the past three months [1] - The Hong Kong Stock Connect Innovative Drug Selection Index dropped by 3.58%, with the latest price of the corresponding ETF (520690) at 0.94 CNY, reflecting a decline of 2.28% [2] - The CSI Pharmaceutical 50 Index decreased by 1.24%, with the latest price of the Pharmaceutical 50 ETF (159838) at 0.63 CNY, showing an 11.34% increase over the past three months [2] Liquidity and Trading Activity - The Hang Seng Healthcare ETF had a turnover of 12.72% and a trading volume of 884 million CNY, indicating active market participation [1] - The Hong Kong Innovative Drug Selection ETF recorded a turnover of 21.74% with a trading volume of 90.47 million CNY [2] - The Pharmaceutical 50 ETF had a turnover of 1.01% and a trading volume of 1.66 million CNY, with an average daily trading volume of 6.33 million CNY over the past week [3] Regulatory and Market Developments - The National Healthcare Security Administration issued a notice to strengthen the regulation of retail pharmacies, targeting "dual pricing" practices, which may accelerate compliance in the pharmacy sector [3] - Boteng Co., Ltd. expects a revenue growth of 17%-21% year-on-year for the first three quarters, indicating a recovery in the CDMO sector driven by global client pipeline expansion [3] - Four Seasons Pharmaceutical has acquired a stake in Swiss Suisselle SA, gaining exclusive rights to the CELLBOOSTER® product, enhancing its international brand collaboration and product matrix [3] Institutional Insights - The overall signal for the pharmaceutical sector is neutral, with regulatory pressures on retail pharmacies but resilience in CDMO and medical aesthetics sectors [4] - Short-term focus is on the sustainability of performance recovery for companies like Boteng, while mid-term attention is on international collaborations in medical aesthetics and growth in the innovative drug outsourcing industry [4] Fund Flows and Performance - The Hang Seng Healthcare ETF saw a net inflow of 12.05 million CNY, accumulating 177 million CNY over the past 15 trading days [6] - The Hong Kong Innovative Drug Selection ETF reached a record high of 434 million shares, with a net inflow of 2.89 million CNY recently [7] - The CSI Pharmaceutical 50 Index includes major companies like WuXi AppTec and Hengrui Medicine, with the top ten stocks accounting for 59.46% of the index [8]

Core Insights - In the first three quarters of this year, 98% of the 976 comparable ordinary equity funds achieved positive performance, with only 23 funds experiencing declines [1] Group 1: Top Performing Funds - The top four performing ordinary equity funds, namely Huaan Pharmaceutical Biotechnology Stock A, Huaan Pharmaceutical Biotechnology Stock C, E Fund Information Industry Select Stock A, and E Fund Information Industry Select Stock C, all saw their performance double, with increases of 103.31%, 102.65%, 102.03%, and 101.26% respectively [1] - Huaan Pharmaceutical Biotechnology Stock's second-quarter report indicates heavy investments in companies such as Innovent Biologics, CSPC Pharmaceutical Group, and others, with significant stock price increases, particularly for 3SBio, which surged over four times [1] - E Fund Information Industry Select Stock's top ten holdings are primarily in the semiconductor sector, including companies like NewEase, Huitian Technology, and Tencent Holdings [1] Group 2: Fund Management and Performance - The E Fund Information Industry Select Stock is managed by Zheng Xi, who has extensive experience in equity investment management and has held various roles within E Fund [2] - Other notable funds such as E Fund Strategic Emerging Industries Stock A and C, and Jiashi Mutual Selection Stock A and C, also reported over 90% increases in the first three quarters [2] - Jiashi Mutual Selection Stock focuses on pharmaceutical stocks, with major holdings in companies like Innovent Biologics and Hengrui Medicine, managed by Hao Miao, who has a strong background in biomedical research [2] Group 3: Underperforming Funds - The fund with the largest decline, Minsheng Jianyin Preferred Stock, fell by 7.39%, primarily investing in blue-chip consumer stocks [4] - The fund's top ten holdings include companies like CATL and BYD, with the current manager, Liu Hao, having less than a year of experience [4] - Other underperforming funds include Changxin Consumer Select Quantitative Stock and Qianhai Kaiyuan Traditional Chinese Medicine Stock, both down by over 5% [4]

Investment Rating - The report suggests a positive outlook for the oligonucleotide drug industry, indicating that it is on the verge of a therapeutic paradigm revolution, particularly in the treatment of common diseases [3]. Core Insights - The oligonucleotide drug market is approaching a critical point of explosion, with significant advancements in delivery technologies and therapeutic targets [3]. - The report highlights the potential for multiple innovative treatment paradigms for common liver diseases over the next five years, focusing on lipid-lowering, blood pressure reduction, and hepatitis B [3]. - The report emphasizes the importance of differentiated delivery technologies and the potential for business development (BD) opportunities in the industry [3]. Summary by Sections Industry Overview - The report revisits the previous assessment from January 2021, which predicted that oligonucleotide drugs would become the third major class of therapeutics after small molecules and monoclonal antibodies [3]. - It notes that the market has seen a significant increase in the number of approved siRNA/ASO drugs since 2022, addressing unmet medical needs [4]. Market Dynamics - The report identifies key players in the industry, including Alnylam, Arrowhead, and Ionis, and discusses their market capitalization changes from 2021 to 2025, highlighting Alnylam's significant growth due to successful drug launches [7]. - It mentions that the market for oligonucleotide drugs is expanding into common diseases, with Alnylam's drugs like Amvuttra and Inclisiran showing strong sales potential [20]. Technological Advancements - The report discusses advancements in delivery technologies, particularly the GalNAc conjugation platform, which has significantly improved the efficacy and safety of oligonucleotide drugs [41][42]. - It highlights the ongoing research into dual-target oligonucleotide drugs, which may become a new trend in the industry [36]. Competitive Landscape - The report outlines the competitive landscape, noting that multinational corporations (MNCs) are actively acquiring clinical-stage FIC drugs and exploring collaborations with biotech firms [3]. - It emphasizes the need for targeted delivery systems for different organs, indicating that the advancement and differentiation of delivery platforms will be crucial for the future success of oligonucleotide drug companies [26][27].